Gyeonggi-do

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Colorectal cancer2 trials
• Multiple myeloma2 trials
• Endometrial cancer1 trial
• Ovarian cancer1 trial
• Prostate cancer1 trial

Phase

• Phase 36 trials
• Phase 1/21 trial
• Phase 21 trial
• Phase 2/31 trial

Status

• Active, not recruiting4 trials
• Recruiting4 trials
• Completed1 trial

Lead sponsor

• GlaxoSmithKline9 trials

Running trials

• Recruiting

  A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]

  NCT07802704· Phase 3· GlaxoSmithKline· Source

  Contact: Jae-Young Joung (principal investigator)

• Recruiting

  A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

  NCT07286266· Phase 3· GlaxoSmithKline· Source

  Contact: Myong Cheol Lim (principal investigator)

• Recruiting

  A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

  NCT07099898· Phase 3· GlaxoSmithKline· Source

  Contact: Beung Chul Ahn (principal investigator)

• Active, not recruiting

  A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

  NCT06710847· Phase 1/2· GlaxoSmithKline· Source

• Recruiting

  Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

  NCT05855200· Phase 3· GlaxoSmithKline· Source

  Contact: Chan Kim (principal investigator)

• Active, not recruiting

  Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

  NCT04655976· Phase 2/3· GlaxoSmithKline· Source

• Active, not recruiting

  Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

  NCT04484623· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT04162210· Phase 3· GlaxoSmithKline· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• Lung cancer1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

  NCT03739710· Phase 2· GlaxoSmithKline· Source